News Focus
News Focus
Followers 124
Posts 7401
Boards Moderated 1
Alias Born 12/03/2017

Re: Dyno89 post# 180359

Thursday, 06/29/2023 10:46:17 AM

Thursday, June 29, 2023 10:46:17 AM

Post# of 202304
Dyno, and everyone here, this is exactly why I have been so salty and worried about this deal. They never tell us what happens to ENZC? Based on what is said in the PR, it seems the AI is IP of BGEN, not ENZC. So once this deal goes though, ENZC no longer owns the AI platform. The fact that they continue to intentionally omit details about what the plan is for ENZC, is 100% cause for concern.

Whether or not $450M is a good price for this and/or for shareholders is 100% dependent on what happens to ENZC. $450M puts the pps around .16, but then we no longer own the AI platform. Once again, this is exactly why I've been asking about how anyone can view our mgmt team moving to BGEN & VIRO as a good thing? I hope I'm dead wrong here, but what it leads me to believe that commons are all gonna end up with the equivalent of an RS, without actually doing an RS. We'll get shares in SAGA, but will likely be somewhere around 1/100th to 1/1000th of the shares we hold in ENZC. I really hope I'm wrong here, but why are they intentionally ommitting what happens with ENZC? Do we even own any IP at all after this deal?

The funds are to be used by BGEN to complete the production of and test species-specific monoclonal antibodies (mAbs) for treating COVID-19, HIV, and Feline Leukemia. The funding will significantly enhance BGEN's drug discovery capabilities using its proprietary, cutting-edge Artificial Intelligence (AI) technology and enlarge its IP portfolio while also expanding the AI platform's capabilities to advance health care from that based on reactive disease care to P4 medicine, namely care that is predictive, preventive, personalized and participatory.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y